Charles Schwab’s Pacific Biosciences PACB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.46M | Buy |
2,652,298
+246,802
| +10% | +$359K | ﹤0.01% | 2531 |
|
|
2026
Q1 | $3.18M | Sell |
2,405,496
-60,357
| -2% | -$108K | ﹤0.01% | 2586 |
|
|
2025
Q4 | $4.61M | Buy |
2,465,853
+38,499
| +2% | +$74K | ﹤0.01% | 2491 |
|
|
2025
Q3 | $3.11M | Buy |
2,427,354
+137,425
| +6% | +$186K | ﹤0.01% | 2633 |
|
|
2025
Q2 | $2.84M | Buy |
2,289,929
+168,405
| +8% | +$194K | ﹤0.01% | 2569 |
|
|
2025
Q1 | $2.5M | Sell |
2,121,524
-54,728
| -3% | -$84K | ﹤0.01% | 2540 |
|
|
2024
Q4 | $3.98M | Buy |
2,176,252
+135,949
| +7% | +$265K | ﹤0.01% | 2442 |
|
|
2024
Q3 | $3.47M | Buy |
2,040,303
+82,807
| +4% | +$136K | ﹤0.01% | 2536 |
|
|
2024
Q2 | $2.68M | Sell |
1,957,496
-30,023
| -2% | -$60.6K | ﹤0.01% | 2598 |
|
|
2024
Q1 | $7.45M | Buy |
1,987,519
+20,682
| +1% | +$121K | ﹤0.01% | 2131 |
|
|
2023
Q4 | $19.3M | Buy |
1,966,837
+127,855
| +7% | +$1.05M | ﹤0.01% | 1620 |
|
|
2023
Q3 | $15.4M | Buy |
1,838,982
+58,556
| +3% | +$669K | ﹤0.01% | 1662 |
|
|
2023
Q2 | $23.7M | Buy |
1,780,426
+40,017
| +2% | +$486K | 0.01% | 1378 |
|
|
2023
Q1 | $20.2M | Buy |
1,740,409
+160,015
| +10% | +$1.59M | 0.01% | 1471 |
|
|
2022
Q4 | $12.9M | Buy |
1,580,394
+28,287
| +2% | +$244K | ﹤0.01% | 1710 |
|
|
2022
Q3 | $9.01M | Sell |
1,552,107
-115,772
| -7% | -$664K | ﹤0.01% | 1903 |
|
|
2022
Q2 | $7.37M | Buy |
1,667,879
+39,937
| +2% | +$243K | ﹤0.01% | 1999 |
|
|
2022
Q1 | $14.8M | Buy |
1,627,942
+36,617
| +2% | +$422K | ﹤0.01% | 1733 |
|
|
2021
Q4 | $32.6M | Buy |
1,591,325
+145,480
| +10% | +$3.51M | 0.01% | 1207 |
|
|
2021
Q3 | $36.9M | Buy |
1,445,845
+11,545
| +0.8% | +$342K | 0.01% | 1075 |
|
|
2021
Q2 | $50.2M | Buy |
1,434,300
+72,151
| +5% | +$2.1M | 0.02% | 867 |
|
|
2021
Q1 | $45.4M | Buy |
1,362,149
+147,677
| +12% | +$5.17M | 0.02% | 905 |
|
|
2020
Q4 | $31.5M | Buy |
1,214,472
+82,859
| +7% | +$1.41M | 0.01% | 1065 |
|
|
2020
Q3 | $11.2M | Buy |
1,131,613
+183,424
| +19% | +$1.06M | 0.01% | 1618 |
|
|
2020
Q2 | $3.27M | Buy |
948,189
+65,560
| +7% | +$223K | ﹤0.01% | 2224 |
|
|
2020
Q1 | $2.7M | Buy |
882,629
+17,531
| +2% | +$71.8K | ﹤0.01% | 2145 |
|
|
2019
Q4 | $4.45M | Buy |
865,098
+17,401
| +2% | +$88.4K | ﹤0.01% | 2081 |
|
|
2019
Q3 | $4.38M | Buy |
847,697
+35,338
| +4% | +$198K | ﹤0.01% | 2031 |
|
|
2019
Q2 | $4.92M | Buy |
812,359
+27,447
| +3% | +$192K | ﹤0.01% | 1980 |
|
|
2019
Q1 | $5.67M | Buy |
784,912
+32,569
| +4% | +$236K | ﹤0.01% | 1922 |
|
|
2018
Q4 | $5.57M | Buy |
752,343
+78,493
| +12% | +$497K | ﹤0.01% | 1851 |
|
|
2018
Q3 | $3.65M | Buy |
673,850
+59,562
| +10% | +$256K | ﹤0.01% | 2209 |
|
|
2018
Q2 | $2.18M | Buy |
614,288
+95,551
| +18% | +$265K | ﹤0.01% | 2349 |
|
|
2018
Q1 | $1.06M | Buy |
518,737
+91,535
| +21% | +$238K | ﹤0.01% | 2497 |
|
|
2017
Q4 | $1.13M | Buy |
427,202
+18,564
| +5% | +$65K | ﹤0.01% | 2475 |
|
|
2017
Q3 | $2.15M | Buy |
408,638
+132,379
| +48% | +$569K | ﹤0.01% | 2261 |
|
|
2017
Q2 | $984K | Sell |
276,259
-77,558
| -22% | -$313K | ﹤0.01% | 2464 |
|
|
2017
Q1 | $1.83M | Buy |
353,817
+23,594
| +7% | +$115K | ﹤0.01% | 2231 |
|
|
2016
Q4 | $1.25M | Buy |
330,223
+31,859
| +11% | +$231K | ﹤0.01% | 2361 |
|
|
2016
Q3 | $2.67M | Buy |
298,364
+163,064
| +121% | +$1.36M | ﹤0.01% | 1998 |
|
|
2016
Q2 | $952K | Buy |
135,300
+19,300
| +17% | +$176K | ﹤0.01% | 2366 |
|
|
2016
Q1 | $986K | Buy |
116,000
+17,500
| +18% | +$172K | ﹤0.01% | 2353 |
|
|
2015
Q4 | $1.29M | Buy |
98,500
+12,900
| +15% | +$116K | ﹤0.01% | 2276 |
|
|
2015
Q3 | $314K | Hold |
85,600
| – | – | ﹤0.01% | 2812 |
|
|
2015
Q2 | $494K | Hold |
85,600
| – | – | ﹤0.01% | 2677 |
|
|
2015
Q1 | $500K | Hold |
85,600
| – | – | ﹤0.01% | 2624 |
|
|
2014
Q4 | $672K | Hold |
85,600
| – | – | ﹤0.01% | 2515 |
|
|
2014
Q3 | $421K | Hold |
85,600
| – | – | ﹤0.01% | 2649 |
|
|
2014
Q2 | $530K | Hold |
85,600
| – | – | ﹤0.01% | 2603 |
|
|
2014
Q1 | $458K | Hold |
85,600
| – | – | ﹤0.01% | 2617 |
|
|
2013
Q4 | $448K | Hold |
85,600
| – | – | ﹤0.01% | 2630 |
|
|
2013
Q3 | $501K | Hold |
85,600
| – | – | ﹤0.01% | 2547 |
|
|
2013
Q2 | $220K | Buy |
+85,600
| New | +$213K | ﹤0.01% | 2857 |
|
Other funds holding PACB
AIM
NAMA
Charles Schwab's PACB Position: Q2 2026 in Review
Charles Schwab increased its Pacific Biosciences (PACB) stake by 10% in Q2 2026, buying an estimated $359K and bringing the position to 2,652,298 shares worth $4.46M. The position accounts for ﹤0.01% of the portfolio, ranked #2531.
Charles Schwab first reported a position in PACB in Q2 2013 and has held it in 53 quarters since. The position peaked at $50.2M in Q2 2021. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.
- Charles Schwab held 2,652,298 shares of Pacific Biosciences worth $4.46M as of Q2 2026.
- Charles Schwab bought 246,802 Pacific Biosciences shares in Q2 2026, an estimated $359K.
- Pacific Biosciences made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2531 holding.
- Charles Schwab first reported a position in Pacific Biosciences in Q2 2013 and has held it in 53 quarters since.
- Charles Schwab's Pacific Biosciences position peaked at $50.2M in Q2 2021.
- 223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.
Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.